Edgar Filing: Symmetry Medical Inc.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 29, 2012

Commission File Number: 001-32374

SYMMETRY MEDICAL INC.

(Exact name of registrant as specified in its charter)

Delaware		35-1996126
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

3724 North State Road 15, Warsaw, Indiana		46582
(Address of principal executive offices)		(Zip Code)

(574) 268-2252
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. þ Yes ¨ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (S232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

þ Yes ¨ No

Indicate by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

	Large accelerated filer ¨		Accelerated filer þ
	Non-accelerated filer ¨ (Do not check if a smaller reporting company)		Smaller reporting company ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ¨ Yes þ No

The number of shares outstanding of the registrant’s common stock as of November 8, 2012 was 36,787,515 shares.

TABLE OF CONTENTS

PART I FINANCIAL INFORMATION

Item 1	Financial Statements:	4

	Condensed Consolidated Balance Sheets: As of September 29, 2012 and December 31, 2011	4

	Condensed Consolidated Statements of Operations: Three and Nine Months Ended September 29, 2012 and October 1, 2011	5

	Condensed Consolidated Statements of Comprehensive Income: Three and Nine Months Ended September 29, 2012 and October 1, 2011	6

	Condensed Consolidated Statements of Cash Flows: Nine Months Ended September 29, 2012 and October 1, 2011	7

	Notes to Condensed Consolidated Financial Statements	8

Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	18

Item 3	Quantitative and Qualitative Disclosures about Market Risk	27

Item 4	Controls and Procedures	27

PART II OTHER INFORMATION

Item 1A	Risk Factors	28

Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	28

Item 6	Exhibits	28

Signatures		29

Cautionary Note Regarding Forward-Looking Statements

Throughout this Quarterly Report on Form 10-Q or in other reports or registration statements filed from time to time with the Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934, or under the Securities Act of 1933, as well as in documents we incorporate by reference or in press releases or oral statements made by our officers or representative, we may make statements that express our opinions, expectations or projections regarding future events or future results, in contrast with statements that reflect historical facts. These predictive statements, which we generally precede or accompany by such typical conditional words such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “potential,” or “expect,” or by the words “may,” “will,” “could,” or “should,” and similar expressions or terminology are intended to operate as “forward-looking statements” of the kind permitted by the Private Securities Litigation Reform Act of 1995. That legislation protects such predictive statements by creating a “safe harbor” from liability in the event that a particular prediction does not turn out as anticipated.

Forward-looking statements convey our current expectations or forecast future events. While we always intend to express our best judgment when we make statements about what we believe will occur in the future, and although we base these statements on assumptions that we believe to be reasonable when made, these forward-looking statements are not a guarantee of performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many uncertainties and other variable circumstances, many of which are outside of our control, that could cause our actual results and experience to differ materially from those we thought would occur.

We also refer you to and believe that you should carefully read the “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors” portions of our Annual Report for fiscal 2011 on Form 10-K, as well as in other reports which we file with the Securities and Exchange Commission, to better understand the risks and uncertainties that are inherent in our business and in owning our securities. These reports are available publicly on the SEC website, www.sec.gov, and on our website, www.symmetrymedical.com.

Any forward-looking statements which we make in this report or in any of the documents that are incorporated by reference herein speak only as of the date of such statement, and we undertake no ongoing obligation to update such statements. Comparisons of results between current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.

PART I FINANCIAL INFORMATION

ITEM I. FINANCIAL STATEMENTS

SYMMETRY MEDICAL INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In Thousands)

	September 29,		December 31,
	2012		2011
	(unaudited)
ASSETS:
Current Assets:
Cash and cash equivalents	$	12,366	$	18,931
Accounts receivable, net		53,035		51,835
Inventories		72,872		84,678
Refundable income taxes		3,866		5,090
Deferred income taxes		10,290		7,535
Derivative valuation asset		179		-
Other current assets		4,005		4,863

Total current assets		156,613		172,932
Property and equipment, net		100,760		103,363
Goodwill		228,783		229,112
Intangible assets, net of accumulated amortization		118,414		124,276
Other assets		8,203		9,182

Total Assets	$	612,773	$	638,865

LIABILITIES AND SHAREHOLDERS' EQUITY:
Current Liabilities:
Accounts payable	$	26,655	$	23,343
Accrued wages and benefits		11,786		7,637
Other accrued expenses		7,366		5,825
Accrued income taxes		67		522
Derivative valuation liability		495		-
Deferred income taxes		-		39
Revolving line of credit		718		6,567
Current portion of capital lease obligations		522		483
Current portion of long-term debt		11,111		5,904

Total current liabilities		58,720		50,320
Accrued income taxes		6,981		6,844
Deferred income taxes		19,989		18,459
Derivative valuation liability		3,868		-
Other liabilities		654		619
Capital lease obligations, less current portion		1,514		1,907
Long-term debt, less current portion		210,777		259,317

Total Liabilities		302,503		337,466

Commitments and contingencies

Shareholders' Equity:
Common Stock, $.0001 par value; 75,000 shares authorized; shares issued September 29, 2012--36,788; December 31, 2011--36,426		4		4
Additional paid-in capital		286,619		283,071
Retained earnings		23,344		17,140
Accumulated other comprehensive income		303		1,184

Total Shareholders' Equity		310,270		301,399

Total Liabilities and Shareholders' Equity	$	612,773	$	638,865

See accompanying notes to condensed consolidated financial statements.

SYMMETRY MEDICAL INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In Thousands, Except per Share Data; Unaudited)

	Three Months Ended						Nine Months Ended
	September 29,			October 1,			September 29,			October 1,
	2012			2011			2012			2011

Revenue	$	100,929		$	84,039		$	303,949		$	274,538
Cost of revenue		72,703			68,285			223,808			217,233
Gross profit		28,226			15,754			80,141			57,305
Research and development expenses		1,293			966			2,998			3,031
Sales and marketing expenses		6,107			4,140			19,868			13,354
General and administrative expenses		10,730			8,733			32,331			26,084
Facility closure and severance		(76	)		253			596			2,526
Operating Income		10,172			1,662			24,348			12,310

Other (income) expense:
Interest expense		4,737			964			14,905			2,754
Derivatives valuation gain		(116	)		-			(179	)		-
Other		(108	)		(160	)		(562	)		591
Income before income taxes		5,659			858			10,184			8,965
Income tax expense		1,921			331			3,980			2,901
Net income	$	3,738		$	527		$	6,204		$	6,064

Net income per share:
Basic	$	0.10		$	0.01		$	0.17		$	0.17
Diluted	$	0.10		$	0.01		$	0.17		$	0.17

Weighted average common shares and equivalent shares outstanding:
Basic		36,044			35,546			35,951			35,537
Diluted		36,512			36,021			36,360			36,000

See accompanying notes to condensed consolidated financial statements.

SYMMETRY MEDICAL INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In Thousands; Unaudited)

	Three Months Ended						Nine Months Ended
	September 29,			October 1,			September 29,			October 1,
	2012			2011			2012			2011

Net income	$	3,738		$	527		$	6,204		$	6,064
Other comprehensive income (loss)
Foreign currency translation adjustments		2,367			(4,378	)		1,799			698
Net unrealized losses on derivative instruments:
Unrealized holding losses, net of taxes		(480	)		-			(2,634	)		-
Reclassification adjustment for realized losses included in net income		(46	)		-			(46	)		-

Comprehensive income (loss)	$	5,579		$	(3,851	)	$	5,323		$	6,762

See accompanying notes to condensed consolidated financial statements.

SYMMETRY MEDICAL INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW

(In Thousands; Unaudited)

	Nine Months Ended
	September 29,			October 1,
	2012			2011

Operating activities
Net income	$	6,204		$	6,064
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation		12,869			13,811
Amortization of intangible assets		6,037			2,138
Amortization of debt issuance costs		1,289			253
Interest paid in kind		1,002			-
Net (gain) loss on sale of assets		(96	)		77
Deferred income tax provision		507			(283	)
Excess tax benefit from stock-based compensation		(294	)		-
Stock-based compensation		3,076			2,174
Derivative valuation gain		(179	)		-
Foreign currency transaction gain		(173	)		(1,474	)
Change in operating assets and liabilities:
Accounts receivable		(720	)		2,873
Other assets		583			(1,499	)
Inventories		12,663			(8,093	)
Current income taxes		762			(2,215	)
Accounts payable		2,518			(942	)
Accrued expenses and other		5,912			5,314

Net cash provided by operating activities		51,960			18,198

Investing activities
Purchases of property and equipment		(9,128	)		(10,426	)
Proceeds from the sale of property and equipment		319			113
Acquisitions		-			(11,000	)

Net cash used in investing activities		(8,809	)		(21,313	)

Financing activities
Proceeds from Bank Revolver		21,839			52,819
Payments on Bank Revolver		(62,712	)		(45,319	)
Proceeds from (payments on) short term borrowings, net		(5,844	)		2,441
Payments on bank term loans and capital lease obligations		(3,490	)		(1,432	)
Proceeds from the issuance of common stock, net		178			79
Excess tax benefit from stock-based compensation		294			-

Net cash provided by (used in) financing activities		(49,735	)		8,588
Effect of exchange rate changes on cash		19			19

Net increase (decrease) in cash and cash equivalents		(6,565	)		5,492
Cash and cash equivalents at beginning of period		18,931			15,067

Cash and cash equivalents at end of period	$	12,366		$	20,559

Supplemental disclosures:
Cash paid for interest	$	11,904		$	2,441

Cash paid for income taxes	$	2,363		$	5,316

See accompanying notes to condensed consolidated financial statements.

SYMMETRY MEDICAL INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(In Thousands, Except Per Share Data; Unaudited)

1. Basis of Presentation

The condensed consolidated financial statements include the accounts of Symmetry Medical Inc. and its wholly-owned subsidiaries (collectively referred to as the Corporation), which operates in two reportable segments: (1) Original Equipment Manufacturer (“OEM”) Solutions and (2) Symmetry Surgical. The Corporation is a global supplier of integrated products consisting primarily of surgical instruments, implants and cases to orthopedic and other medical device companies. OEM Solutions primarily designs, develops and manufactures surgical instruments, implants and cases for orthopedic device markets. Symmetry Surgical is the Corporation’s hospital direct business which sells a broad range of reusable stainless steel and titanium surgical hand-held instruments and retractor systems, sterile disposable surgical products, and sterilization containers.

The condensed consolidated financial statements of the Corporation have been prepared without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the accompanying condensed consolidated financial statements contain all adjustments of a normal recurring nature considered necessary to present fairly the consolidated financial position of the Corporation, its results of operations and cash flows. The Corporation’s results are subject to seasonal fluctuations. Interim results are not necessarily indicative of results for a full year. The condensed consolidated financial statements included herein should be read in conjunction with the fiscal year 2011 consolidated financial statements and the notes thereto included in the Corporation’s Annual Report on Form 10-K for fiscal year 2011.

The Corporation’s fiscal year is the 52 or 53 week period ending on the Saturday closest to December 31. Fiscal year 2012 is a 52 week year ending December 29, 2012. The Corporation’s interim quarters for 2012 are 13 weeks long and quarter-end dates have been set as March 31, 2012, June 30, 2012 and September 29, 2012. Fiscal year 2011 was a 52 week year (ending December 31, 2011). The Corporation’s interim quarters for 2011 were 13 weeks long, ending April 2, 2011, July 2, 2011 and October 1, 2011. References in these condensed consolidated financial statements to the three months ended refer to these financial periods, respectively.

2. Acquisitions

Results of the following acquisitions are included in the statement of operations from the date of acquisition.

On August 15, 2011, the Corporation acquired substantially all of the assets of PSC’s Olsen Medical division (Olsen Medical) for $11,000 in cash. Olsen Medical manufactures a full line of single-use and reusable bipolar and monopolar forceps, cords, electrosurgical pens/pencils, electrodes, and accessories. Olsen Medical’s products are primarily sold directly to hospitals in the U.S. and internationally through distributors.

The aggregate purchase price of $11,000 was allocated to the opening balance sheet as follows:

Current assets	$	3,001
PP&E		1,003
Acquired customers (amortized over 15 years)		3,040
In process R&D		610
Trademarks (indefinite-lived)		1,190
Goodwill		2,912
Current liabilities		(756	)

Purchase price, net	$	11,000

On December 29, 2011, the Corporation acquired the surgical instruments business of Codman & Shurtleff, Inc., a Johnson & Johnson Company, for $165,687 in cash. Codman surgical instruments include, but are not limited to, reusable stainless steel and titanium surgical hand-held instruments and retractor systems and sterile disposable surgical products.

2. Acquisitions (Continued)

The aggregate purchase price of $165,687 was preliminarily allocated to the opening balance sheet as follows:

Current assets	$	10,431
PP&E		114
Acquired customers (amortized over 20 years)		80,840
Trademarks (indefinite-lived)		3,380
Goodwill		71,710
Current liabilities		(169	)
Long term liabilities		(619	)

Purchase price, net	$	165,687

The purchase price allocation for the acquisition of the Codman surgical instruments business is preliminary and therefore subject to adjustment.

Unaudited Proforma Results. The following table represents the unaudited proforma results of the Corporation's operations had the acquisitions of Codman surgical instruments business and Olsen Medical been completed as of the beginning of the periods presented:

	Three Months Ended		Nine Months Ended
	October 1,		October 1,
	2011		2011
	(unaudited)
Revenue	$	101,599	$	328,721
Net income		2,341		11,126
Earnings per share—basic	$	0.07	$	0.31
Earnings per share—diluted	$	0.06	$	0.31

3. Inventories

Inventories consist of the following:

	September 29,		December 31,
	2012		2011
	(unaudited)
Raw material and supplies	$	14,073	$	17,870
Work-in-process		23,124		30,083
Finished goods		35,675		36,725

	$	72,872	$	84,678

4. Property and Equipment

Property and equipment, including depreciable lives, consists of the following:

	September 29,			December 31,
	2012			2011
	(unaudited)
Land	$	6,580		$	6,399
Buildings and improvements (20 to 40 years)		42,921			41,994
Machinery and equipment (5 to 15 years)		153,406			151,376
Office equipment (3 to 5 years)		19,897			17,042
Construction-in-progress		8,738			5,755

		231,542			222,566
Less accumulated depreciation		(130,782	)		(119,203	)

	$	100,760		$	103,363

5. Debt Arrangements

On December 11, 2011, the Corporation amended its Credit Agreement (Amended Credit Agreement) to add a $50,000 bank term loan (Bank Term Loan) and an option to borrow an additional $50,000 in the form of an increase to the revolving line of credit or additional bank term loans, subject to approval by a majority of the lenders. Thus, the Amended Credit Agreement currently provides for a $200,000 revolving line of credit (Bank Revolver) and $50,000 of a Bank Term Loan.

Borrowings under the Amended Credit Agreement bear interest at a floating rate, which is either a base rate, or at our option, London Interbank Offered Rate ("LIBOR"), plus an applicable margin. The Corporation had two outstanding letters of credit as of September 29, 2012 in the amounts of $2,000 and $100. The Bank Revolver requires no scheduled payments of principal until maturity in November 2015. The Bank Term Loan has quarterly scheduled principal payments of $2,778 beginning September 2012 through maturity in December 2016.

The Amended Credit Agreement contains various financial covenants, including covenants requiring a maximum ratio of total debt to EBITDA (as defined in the Amended Credit Agreement) and minimum fixed charges ratio of EBITDA. The Amended Credit Agreement also contains covenants restricting certain corporate actions, including asset dispositions, acquisitions, payment of dividends and certain other restricted payments, changes of control, incurring indebtedness, incurring liens, making loans and investments and transactions with affiliates. The Amended Credit Agreement is secured by substantially all of the Corporation’s U.S. subsidiary assets and also contains customary events of default. The Corporation was in compliance with all of its covenants as of September 29, 2012.

On December 29, 2011, the Corporation issued $65,000 of senior subordinated term notes (Term Notes) that mature on December 29, 2017. Amounts outstanding under the Term Notes bear interest at an annual rate of 14%. Interest is payable in cash, provided that we may elect to pay up to 2% of the interest rate in kind by adding that amount to the outstanding principal balance with compounding interest to accrue. The Corporation may elect to repay the outstanding principal amount at any time, provided that, (i) with respect to any prepayment made on or prior to December 29, 2013, the Corporation pays a Make-Whole Premium (as defined in the agreement), (ii) with respect to any prepayment made after December 29, 2013 but on or prior to December 29, 2014, the Corporation pays a prepayment premium of 4% of the amount prepaid, and (iii) with respect to any prepayment made after December 29, 2014 but on or prior to December 29, 2015, the Corporation pays a prepayment premium of 2% of the amount prepaid. The Corporation is also required to prepay amounts outstanding under the agreement using the Net Cash Proceeds (as defined in the Term Notes agreement) of certain asset sales and issuances of debt or equity made by the Corporation during the term of the Term Notes, in each case to the extent such Net Cash Proceeds are not used to repay the Corporation's senior indebtedness. The Corporation is also required to make an offer (a "Change in Control Offer") to prepay all of the amounts outstanding under the Term Notes at a price in cash equal to 101% of the outstanding principal amount thereunder in the event of a Change of Control (as defined in the Term Notes agreement). Each lender under the agreement may decline the Corporation's Change in Control offer or elect to accept the Change in Control Offer in whole or in part. All principal and accrued interest under the Term Notes must be repaid on December 29, 2017.

The Term Notes include customary representations, warranties and covenants made for the benefit of the parties to the agreement. The covenants include, but are not limited to, requirements to provide financial information and notice of other events to the lenders, as well as restrictions on the incurrence of indebtedness, the creation or existence of liens, sales of assets, transactions with affiliates and other matters. The Term Notes also include financial covenants, including covenants requiring a maximum ratio of total debt to EBITDA (as defined in the Term Notes Agreement) and ratio of minimum fixed charges to EBITDA. The agreement includes customary events of default, including but not limited to, failure to pay any principal, interest, fees or other amounts when due, default under any covenant or any agreement in any loan document (subject to cure periods in some cases), cross-default with other debt agreements and certain bankruptcy and insolvency events. While not secured by the Corporation’s assets, repayment of amounts outstanding under the Term Notes is guaranteed by all of Symmetry’s U.S. subsidiaries. The Corporation was in compliance with all of its covenants as of September 29, 2012.

In April 2012, our Penang, Malaysia unit renewed its existing short-term revolving line of credit of $8,000 which is renewable on an annual basis. During June 2012, this agreement was amended to reduce the available limit to $2,000. The facility requires interest only monthly payments at LIBOR, plus an applicable margin per year and the total outstanding amount is due upon maturity in April 2013. As of September 29, 2012, $718 was outstanding on the facility. Outstanding amounts on this Malaysian facility are secured by a standby letter of credit issued on the Corporation’s U.S. Amended Credit Agreement in the amount of $2,000.

6. New Accounting Pronouncements

Presentation of Comprehensive Income: In June 2011, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2011-05, “Comprehensive Income (ASC Topic 220): Presentation of Comprehensive Income,” (“ASU 2011-05”) which amends current comprehensive income guidance. This accounting update eliminates the option to present the components of other comprehensive income as part of the statement of shareholders’ equity. Instead, the Company must report comprehensive income in either a single continuous statement of comprehensive income which contains two sections, net income and other comprehensive income, or in two separate but consecutive statements. The Corporation adopted the provisions of this standard on January 1, 2012, which did not have an impact on the Corporation’s consolidated financial position, results of operations or cash flows.

Intangibles — Goodwill and Other (Topic 350): Testing Goodwill for Impairment: In September 2011, the FASB issued ASU No. 2011-08, “Intangibles — Goodwill and Other (Topic 350): Testing Goodwill for Impairment” (“ASU 2011-08”). ASU 2011-08 allows companies to have the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If after considering the totality of events and circumstances an entity determines it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test is unnecessary. ASU 2011-08 is effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011, however, early adoption is permitted, including for annual and interim goodwill impairment tests performed as of a date before September 15, 2011. The Corporation adopted ASU 2011-08 on January 1, 2012, but did not elect the option of performing a qualitative assessment. The adoption of ASU 2011-08 did not have an impact on the Corporation’s consolidated financial position, results of operations or cash flows.

7. Derivatives

The Corporation utilizes derivative instruments to minimize the volatility of cash flows and statement of operations impacts associated with interest rate payments on its variable rate debt and the impact of fluctuations in foreign currency. The Corporation recognizes all derivative instruments as either assets or liabilities at fair value on the consolidated balance sheets. The Corporation utilizes third party valuations to assist in the determination of the fair value of these derivatives. The Corporation considered its derivative instrument valuations to be Level 2 fair value measurements.

To the extent a derivative instrument is designated effective as a cash flow hedge of an exposure to changes in the fair value of a future transaction, the change in fair value of the derivative is deferred in accumulated other comprehensive income (loss), a component of shareholders' equity in the consolidated balance sheets, until the underlying transaction hedged is recognized in the consolidated statements of operations. The Corporation accounts for certain derivatives hedging the payment of interest as cash flow hedges and the impact of the hedge is reclassified to interest expense in the consolidated statements of operations upon payment of interest.

The Corporation's profitability and cash flows are affected by changes in interest rates, specifically LIBOR. The primary purpose of the Corporation's interest rate risk management activities is to hedge its exposure to changes in interest rates. The Corporation’s Amended Credit Agreement requires that the interest be hedged on at least 50% of the current and projected borrowings under the Amended Credit Agreement for a period of at least 3 years beginning no later than March 29, 2012. In March 2012, the Corporation entered into two forward swap contracts to manage interest rate risk related to its Bank Term Loan and a portion of its Bank Revolver. The notional amount on the Bank Term Loan swap contract is $25,000 that amortizes in line with scheduled principal payments through maturity in December 2016 and has a fixed per annum interest rate of 0.44% in 2012 that incrementally increases to 2.22% by 2016. The notional amount on the Bank Revolver swap contract is $70,000 that amortizes in line with expected reductions in the related debt instrument through December 2022 and has a fixed per annum interest rate of 0.44% in 2012 that incrementally increase to 3.81% by 2022. These swap contracts, which had a fair value of $4,363 as of September 29, 2012, were designated as cash flow hedges of the future payments of variable rate interest with one-month LIBOR. For the three and nine months ended September 29, 2012, there were losses of $856 and $4,363 attributable to these cash flow hedges included in other comprehensive income, of which approximately $495 will be reclassified into earnings in the next twelve months.

In June and July 2012, the Corporation entered into forward swap contracts to mitigate the impact of fluctuations in foreign currency on the statement of operations. As of September 29, 2012, the Corporation had contracts for the sale of 4,275 Euros which settle in equal amounts over the twelve month period which began July 2012. These swap contracts, which had an aggregate value of $179 at September 29, 2012, were not designated as cash flow hedges and therefore the change in the fair value is immediately recorded in derivatives valuation gain in the unaudited condensed consolidated statements of operations.

8. Fair Value of Financial Instruments

As of September 29, 2012, the Corporation held certain assets that are required to be measured at fair value on a recurring basis. These included the Corporation’s derivative instruments in the form of interest rate swaps and foreign currency forward contracts. The Corporation’s derivative instruments consist of contracts that are not traded on a public exchange. The fair values of interest rate derivative instruments and foreign currency forward contracts are determined based on inputs that are readily available in public markets or can be derived from information available in publicly quoted markets. Therefore, the Corporation has categorized these derivative instruments as Level 2 in accordance with the FASB Standard on fair value measurement.

On a recurring basis management measures the fair value of its interest rate swaps using the market approach based on projections of the one month LIBOR rate over the life of each swap. Also on a recurring basis, management measures the fair value of its foreign currency forward contracts using the market approach based on the projections of the Euro rate over the life of each forward contract. The fair value and carrying value of the Corporation’s assets and liabilities measured at fair value on a recurring basis were as follows:

	September 29, 2012										December 31, 2011
	Fair Value Measurements										Fair Value Measurements
	Level 1		Level 2			Level 3		Total			Level 1		Level 2		Level 3		Total
	(unaudited)
Assets
Cash and cash equivalents	$	-	$	12,366		$	-	$	12,366		$	-	$	18,931	$	-	$	18,931
Foreign currency forwards				179					179					0				0
Total assets	$	-	$	12,545		$	-	$	12,545		$	-	$	18,931	$	-	$	18,931

Liabilities
Interest rate swaps	$	-	$	(4,363	)	$	-	$	(4,363	)	$	-	$	-	$	-	$	-
Total liabilities	$	-	$	(4,363	)	$	-	$	(4,363	)	$	-	$	-	$	-	$	-

Certain nonfinancial assets and liabilities are measured at fair value on a nonrecurring basis and are subject to fair value adjustments in certain circumstances, such as when there is evidence of impairment. Assets and liabilities acquired in business combinations are recorded at their fair value as of the date of acquisition. Refer to Note 2 for the fair values of assets acquired and liabilities assumed in connection with the Olsen Medical and Codman surgical instrumentation business acquisitions.

The Corporation reviews for goodwill impairment annually on October 1 and whenever events or changes in circumstances indicate its carrying value may not be recoverable. The fair value of the reporting units is determined using the income approach. The income approach focuses on the income-producing capability of an asset, measuring the current value of the asset by calculating the present value of its future economic benefits such as cash earnings, cost savings, corporate tax structure and product offerings. Value indications are developed by discounting expected cash flows to their present value at a rate of return that incorporates the risk-free rate for the use of funds, the expected rate of inflation and risks associated with the reporting unit. These assets would generally be classified within Level 3, in the event that the Corporation were required to measure and record such assets at fair value within its unaudited condensed consolidated financial statements.

The Corporation periodically evaluates the carrying value of long-lived assets to be held and used, including definite-lived intangible assets and property plant and equipment, when events or circumstances warrant such a review. Fair value is determined primarily using anticipated cash flows assumed by a market participant discounted at a rate commensurate with the risk involved and these assets would generally be classified within Level 3, in the event that the Company were required to measure and record such assets at fair value within its unaudited condensed consolidated financial statements.

Additionally, financial instruments also consist of cash and cash equivalents, accounts receivable, accounts payable and long-term debt. The carrying value of these financial instruments materially approximates fair value. Additionally, the fair value of cash and cash equivalents and net accounts receivables and payables was estimated by management to approximate fair value due to the relatively short period of time to maturity for these instruments.

9. Segment Reporting

In connection with the Codman surgical instrumentation & the Olsen Medical acquisitions and the CEO’s implementation of a new reporting structure, the Corporation determined that they had two reportable segments as of December 31, 2011 under the provisions of ASC 820 as opposed to one as of January 1, 2011: OEM Solutions and Symmetry Surgical. OEM Solutions primarily designs, develops and manufactures surgical instruments, implants and cases for orthopedic device companies and companies in other medical device markets such as arthroscopy, dental, laparoscopy, osteobiologic and endoscopy. OEM Solutions also manufactures specialized non-healthcare products, primarily in the aerospace industry. OEM Solutions manages its business in multiple operating segments. Because of the similar economic characteristics of these operations, including the nature of the products, comparable level of FDA regulations, and same or similar customers, those operations have been aggregated for segment reporting purposes. Symmetry Surgical is the Corporation’s hospital direct business which sells a broad range of reusable stainless steel and titanium surgical hand-held instruments and retractor systems, sterile disposable surgical products (vein strippers, SECTO dissectors, tonsil sponges and surgical marker pens), and sterilization containers. These products are typically used in the surgical specialties of spine, general/OB-GYN, microsurgery/neurosurgery, orthopedics, laparoscopy, cardiovascular, thoracic and general surgery in the hospital setting, as well as surgery centers and in select physician offices. Symmetry Surgical was formed upon the acquisition of the surgical instrumentation business of Codman.

The Corporation is a multi-national company with operations in the U.S., United Kingdom, France, Ireland, Malaysia and Germany. As a result, the Corporation's financial results can be impacted by currency exchange rates in the foreign markets in which the Corporation sells its products. Revenues are attributed to geographic locations based on the location to which products are shipped.

The accounting policies of the segments are the same as those described in the summary of significant accounting policies in the Corporation’s 2011 10-K, except that the Corporation evaluates segment performance based on income from operations. Beginning January 1, 2012, the Corporation began allocating certain administrative corporate charges to the OEM Solutions and Symmetry Surgical reportable segments. Prior periods have been restated to reflect the allocation of these charges. Other Corporation charges, such as interest, income taxes and remaining unallocated administrative charges have not been allocated to the OEM Solutions or Symmetry Surgical reportable segments. The Corporation generally accounts for intersegment sales and transfers at cost plus a specified mark-up.

Reportable segment information is as follows:

	Three Months Ended September 29, 2012
	OEM Solutions		Symmetry Surgical		Unallocated			Combined segments		Eliminations			Consolidated Total
	(unaudited)
Revenues
External revenues	$	76,132	$	24,797		-		$	100,929		-		$	100,929
Intersegment revenues		2,703		74		-			2,777	$	(2,777	)		-
Total revenues		78,835		24,871		-			103,706		(2,777	)		100,929

Depreciation and amortization		4,488		1,642	$	54			6,184		-			6,184

Operating income (loss)		9,394		4,298		(3,328	)		10,364		(192	)		10,172
Interest expense														4,737
Derivatives valuation gain														(116	)
Other														(108	)
Income before income taxes														5,659

9. Segment Reporting (Continued)

	Three Months Ended October 1, 2011
	OEM Solutions		Symmetry Surgical		Unallocated			Combined segments		Eliminations			Consolidated Total
	(unaudited)
Revenues
External revenues	$	73,538	$	10,501		-		$	84,039				$	84,039
Intersegment revenues		1,065		230		-			1,295	$	(1,295	)		-
Total revenues		74,603		10,731		-			85,334		(1,295	)		84,039

Depreciation and amortization		4,985		267	$	53			5,305					5,305

Operating income (loss)		3,957		384		(2,695	)		1,646		16			1,662
Interest expense														964
Other														(160	)
Income before income taxes														858

	Nine Months Ended September 29, 2012
	OEM Solutions		Symmetry Surgical		Unallocated			Combined segments		Eliminations			Consolidated Total
	(unaudited)
Revenues
External revenues	$	225,178	$	78,771		-		$	303,949		-		$	303,949
Intersegment revenues		6,854		292		-			7,146	$	(7,146	)		-
Total revenues		232,032		79,063		-			311,095		(7,146	)		303,949

Depreciation and amortization		13,895		4,850	$	161			18,906		-			18,906

Operating income (loss)		18,047		15,085		(8,679	)		24,453		(105	)		24,348
Interest expense														14,905
Derivatives valuation gain														(179	)
Other														(562	)
Income before income taxes														10,184

	Nine Months Ended October 1, 2011
	OEM Solutions		Symmetry Surgical		Unallocated			Combined segments		Eliminations			Consolidated Total
	(unaudited)
Revenues
External revenues	$	246,265	$	28,273		-		$	274,538				$	274,538
Intersegment revenues		5,091		309		-			5,400	$	(5,400	)		-
Total revenues		251,356		28,582		-			279,938		(5,400	)		274,538

Depreciation and amortization		15,096		699	$	154			15,949					15,949

Operating income (loss)		21,311		330		(9,337	)		12,304		6			12,310
Interest expense														2,754
Other														591
Income before income taxes														8,965

9. Segment Reporting (Continued)

Revenues to External Customers:

	Three Months Ended				Nine Months Ended
	September 29,		October 1,		September 29,		October 1,
	2012		2011		2012		2011
	(unaudited)				(unaudited)
United States	$	73,473	$	60,541	$	223,124	$	198,293
Ireland		5,432		5,507		16,455		18,117
United Kingdom		8,036		6,590		22,489		22,149
Other foreign countries		13,988		11,401		41,881		35,979

Total revenues	$	100,929	$	84,039	$	303,949	$	274,538

Concentration of Credit Risk:

A substantial portion of the Corporation's revenues is derived from a limited number of customers. Revenue from customers of the Corporation which individually account for 10% or more of the Corporation's revenue is as follows:

Three months ended September 29, 2012— One customer represented approximately 32.3% of revenue, however, excluding the Codman related transitional services agreement, this customer would represent 29.9%.

Nine months ended September 29, 2012— One customer represented approximately 32.6% of revenue, however, excluding the Codman related transitional services agreement, this customer would represent 29.6%.

Three months ended October 1, 2011— Two customers represented approximately 28.5% and 12.7% of revenue, respectively.

Nine months ended October 1, 2011— Two customers represented approximately 31.5% and 11.1% of revenue, respectively.

Following is a summary of the composition by segment and product category of the Corporation's revenues to external customers.

	Three Months Ended				Nine Months Ended
	September 29,		October 1,		September 29,		October 1,
Sales by product	2012		2011		2012		2011
	(unaudited)				(unaudited)
OEM Solutions Revenue
Instrument	$	29,633	$	24,802	$	85,197	$	87,933
Implant		25,632		26,735		75,499		80,436
Cases		14,209		15,853		44,569		59,952
Other		6,658		6,148		19,913		17,944
Total OEM Solutions Revenue		76,132		73,538		225,178		246,265

Total Symmetry Surgical Revenue		24,797		10,501		78,771		28,273

Total Revenue	$	100,929	$	84,039	$	303,949	$	274,538

10. Net Income Per Share

The following table sets forth the computation of earnings per share.

	Three Months Ended				Nine Months Ended
	September 29,		October 1,		September 29,		October 1,
	2012		2011		2012		2011
	(unaudited)				(unaudited)
Earnings per share - Basic:
Net income	$	3,738	$	527	$	6,204	$	6,064

Weighted-average common shares outstanding - Basic		36,044		35,546		35,951		35,537

Earnings per share - Basic	$	0.10	$	0.01	$	0.17	$	0.17

Earnings per share - Diluted:
Net income	$	3,738	$	527	$	6,204	$	6,064

Weighted-average common shares outstanding - Basic		36,044		35,546		35,951		35,537
Effect of dilution		468		475		409		463
Weighted-average common shares outstanding - Diluted		36,512		36,021		36,360		36,000

Earnings per share - Diluted	$	0.10	$	0.01	$	0.17	$	0.17

As of September 29, 2012 and October 1, 2011, the diluted weighted-average share calculations do not include performance based restricted stock awarded in 2012 totaling 273 shares and in 2011 totaling 256 shares, respectively, due to the respective measurement period not being complete.

11. Accounts Receivable Factoring

In January 2012, the Corporation entered into an agreement with an unrelated third-party for the factoring of specific accounts receivable in the UK to reduce the amount of working capital required to fund such receivables. The factoring of accounts receivable under this agreement is accounted for as a sale in accordance with ASC 860, Transfers and Servicing. Proceeds on the transfer reflect the face value of the account less a discount. The discount is recorded as a charge in general and administrative expenses in the consolidated statement of operations in the period of the sale. Net funds received reduced accounts receivable outstanding while increasing cash. The Corporation has no retained interests, nor any continuing involvement or servicing liabilities related to the accounts receivable that have been sold. For the three and nine months ended September 29, 2012, the Corporation had sold $1,644 and $5,299, respectively, of accounts receivable pursuant to this agreement, which represents the face amount of total outstanding receivables at the time the receivables are sold. Fees paid pursuant to this agreement were $12 and $37, respectively, for the three and nine months ended September 29, 2012.

12. Commitments and Contingencies

Legal & Environmental Matters. The Corporation is involved, from time to time, in various contractual, product liability, patent (or intellectual property) and other claims and disputes incidental to its business. Currently, there is no environmental or other litigation pending or, to the knowledge of the Corporation, threatened, that the Corporation expects to have a material adverse effect on its financial condition, results of operations or liquidity. While litigation is subject to uncertainties and the outcome of litigated matters is not predictable with assurance, the Corporation currently believes that the disposition of all pending or, to the knowledge of the Corporation, threatened claims and disputes, individually or in the aggregate, should not have a material adverse effect on the Corporation’s consolidated financial condition, results of operations or liquidity.

Unconditional Purchase Obligations. The Corporation has contracts to purchase minimum quantities of cobalt chrome, nickel and titanium through July 1014. Based on contractual pricing at September 29, 2012, the remaining minimum purchase obligations total $16,229. Purchases under cobalt chrome and titanium contracts total approximately $8,291 for the nine month period ended September 29, 2012. These purchases are not in excess of our forecasted requirements.

13. Facility Closure and Severance

Results of operations include pre-tax charges of ($76) and $253 for the three months ended September 29, 2012 and October 1, 2011, respectively, and $596 and $2,526 for the nine months then ended, associated with employee cost efficiency actions and employee severance costs. As of September 29, 2012 and December 31, 2011, severance accruals related to these cost reduction and efficiency actions totaled $208 and $605, respectively, and are included in other accrued expenses in the consolidated balance sheets. The reduction in the accrual since December 31, 2011 represents payments made and final payout adjustments during 2012. These costs are expected to be paid through July 2013.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Business Overview

Symmetry Medical Inc. is a leading global source of medical device solutions, including surgical instruments, orthopedic implants, and sterilization cases and trays. We employ over 2,500 teammates around the world who are dedicated to being the trusted global source of innovative medical device solutions and surgical instruments for today’s needs and tomorrow’s growth.

In our OEM Solutions segment, we offer our original equipment manufacturer (OEM) customers instruments, implants and sterilization cases and trays. Symmetry Surgical, our growing hospital direct medical distribution business, is complementary to our core competencies and is not competitive with our OEM customers. Our salespeople call on hospital personnel in the operating room, materials management and central sterile departments. Our goal is to offer best-in-class quality and regulatory systems as well as customer innovation through Total Solutions® collaborations.

During the third quarter 2012, Symmetry’s OEM Solutions business revenue increased $2,594, or 3.5%, compared to the third quarter 2011. This increase was primarily driven by increased customer demand in instruments compared to an unusually weak demand and smaller customer launch volume in the third quarter of 2011. Additionally, other product revenue increased as a result of continued strong customer demand in the aerospace industry. These increases were partially offset by foreign currency exchange rates negatively impacting revenue by $1,429 for all products. During the third quarter 2012, our combined five largest OEM customers increased revenue by 9.8% compared to third quarter 2011, primarily driven by increased demand and greater customer launch volume. Our overall OEM Solutions revenue in the third quarter 2012 increased by $1,077 from the second quarter 2012.

During the third quarter 2012, Symmetry Surgical revenue increased $14,296, or 136.1%, compared to the third quarter 2011. This increase was primarily driven by our acquisitions of Codman surgical instruments and Olsen Medical during 2011.

In August, 2011, we acquired the assets of PSC's Olsen Medical division (Olsen Medical) for $11,000 in cash. Olsen Medical manufactures a full line of single-use and reusable bipolar and monopolar forceps, cords, electrosurgical pens/pencils, electrodes, and accessories. Olsen Medical's products are primarily sold in the U. S. and internationally through distributors.

On December 29, 2011, we acquired the surgical instruments product portfolio from Codman & Shurtleff, Inc., a Johnson & Johnson Company for $165,687 in cash. Codman distributes surgical instruments and sterile disposable surgical products directly to hospitals. The addition of Olsen Medical and Codman surgical instruments allows us to offer an expanded array of medical instruments and related products, expand our intellectual property, trademarks, and regulatory approvals, and provides an instrument procurement center and personnel located in Tuttlingen, Germany. Codman's products are sold primarily in the U.S. and internationally through distributors.

The sluggish U.S. economy, high unemployment rates and lower than historical levels of surgical implant procedure growth continued to adversely impact customer demand. However, we continue to be optimistic about our long-term future as the larger OEMs are increasingly focused on improving their supply chains and plan to launch new products with large programs over the next three years. We believe this will result in fewer suppliers who will provide a wider range of services coupled with high quality and reduced overall costs. We believe that we are well positioned to benefit from increased OEM outsourcing and the consolidation of suppliers. In Symmetry Surgical, we plan to continue to expand coverage and product portfolio to serve our hospital direct customers, consistent with our strategic principles.

Our strategic plan is focused on four distinct but synergistic areas:

Being the trusted, industry leading orthopedic OEM supplier positioned to gain share in long-term growth segment;

Diversifying our revenue base with our strategic, growing hospital direct medical device distribution business;

Utilizing resources to pursue growth opportunities and acquisitions in appropriate Medical Device OEM adjacencies and add to hospital solutions portfolio; and

Developing a robust intellectual property portfolio with a dedicated R&D team to drive future growth through innovation.

Using this strategy, we are striving to provide the best possible customer experience by offering superior value; the highest-quality new technology; customized services; superior support; and the combination of our products and services into our Total Solutions® offering. Historically, our growth has been driven organically from our core businesses as well as acquisitions designed to augment select areas of our business with more products, services, and technology.

Third Quarter Results of Operations

Revenue. Revenue for the three month period ended September 29, 2012 increased $16,890, or 20.1%, to $100,929 from $84,039 for the comparable 2011 period. Revenue for each of our segments and principal product categories in these periods was as follows:

	Three Months Ended
	September 29,		October 1,		Dollar			Percent
Sales by product	2012		2011		Change			Change
	(unaudited)
OEM Solution Revenue
Instrument	$	29,633	$	24,802	$	4,831			19.5	%
Implant		25,632		26,735		(1,103	)		-4.1	%
Cases		14,209		15,853		(1,644	)		-10.4	%
Other		6,658		6,148		510			8.3	%
Total OEM Solution Revenue		76,132		73,538		2,594			3.5	%

Total Symmetry Surgical Revenue		24,797		10,501		14,296			136.1	%

Total Revenue	$	100,929	$	84,039	$	16,890			20.1	%

The $2,594 increase in OEM Solutions revenue resulted from increased customer demand within our instruments and other product lines. These increases were offset by reduced customer demand within our implant and cases product lines, in addition to unfavorable foreign currency exchange rate fluctuations of $1,429. Overall, we experienced increased revenues of 9.8% from our five largest OEM customers which drove the increase in revenue. OEM Solutions Instrument revenue increased $4,831. This increase was driven by higher revenue from our top five largest OEM customers of $4,310 related to new customer launches compared to an unusually weak demand and smaller customer launch volume in the third quarter of 2011. OEM Solutions Implant revenue decreased $1,103 driven partially by unfavorable foreign currency exchange rate fluctuations of $614 as well as decreased demand from other customers. These reductions were offset by slightly increased demand from our top five largest OEM customers of $365. Case revenue decreased $1,644 due to both unfavorable foreign currency exchange rate fluctuations of $569 as well as soft customer demand across other medical industries while sales to our top five customers were flat year over year. Increase in OEM Solution Other product revenue was driven by increased demand, which was offset by unfavorable foreign currency exchange rate fluctuations of $107.

The $14,296 increase in Symmetry Surgical revenue for the third quarter 2012 as compared to 2011 was primarily the result of the acquisition of Codman surgical instruments in December 2011 and Olsen Medical in August 2011, which added $13,699 of revenue in 2012 compared to the same period 2011. Excluding the contributions of the acquired businesses, revenue increased $597 due to broader product offerings as compared to the prior year period.

Gross Profit. Gross profit for the three month period ended September 29, 2012 increased $12,472, or 79.2%, to $28,226 from $15,754 for the comparable 2011 period. Gross margin as a percentage of revenue increased 9.3%, to 28.0% for the third quarter 2012 from 18.7% for the comparable 2011 period.

	Three Months Ended
	September 29, 2012
				As a %
	Dollars			of Revenue
	(unaudited)

2011 period reported gross profit	$	15,754			18.7	%
Change in organic sales		866			0.0	%
Impact of acquisitions		8,439			5.9	%
Foreign currency impact		(266	)		0.0	%
Manufacturing costs and other		3,433			3.4	%
2012 period reported gross profit	$	28,226			28.0	%

Gross profit was favorably impacted by $8,439 due to the acquisitions of Olsen Medical and Codman surgical instruments within our Symmetry Surgical segment. Olsen Medical was acquired during third quarter 2011 therefore contributed slightly to gross profit in the prior year period. The Codman surgical instruments business was acquired subsequent to October 1, 2011, therefore did not contribute to gross profit in the prior year period. Excluding the impact of newly acquired businesses and the change in foreign exchange rates, organic revenue improved by $4,620 which positively impacted gross profit by approximately $866. Further, there were improvements to our gross profit from manufacturing costs related primarily to our increased leveraging of overhead costs resulting from higher OEM Solution sales volume, improvements in scrap and consumables, and efficiencies resulting from our lean initiatives.

Research and Development Expenses. For the three month period ended September 29, 2012, research and development expenses increased $327 or 33.9%, to $1,293 from $966 in the comparable period in 2011. This increase was most significantly attributable to the timing of project costs incurred during the third quarter of 2012 compared to the same period in 2011.

Sales and Marketing Expenses. For the three month period ended September 29, 2012, sales and marketing expenses increased $1,967 or 47.5%, to $6,107 from $4,140 in the comparable period in 2011. Significant items which impacted sales and marketing expenses included:

	Three Months Ended
	September 29, 2012
				As a %
	Dollars			of Revenue
	(unaudited)

2011 period reported Sales and Marketing expenses	$	4,140			4.9	%
Impact of acquisitions		2,516
Other		(549	)
2012 period reported Sales and Marketing expenses	$	6,107			6.1	%

The impact of acquisitions reflects higher costs from the acquisitions of Olsen Medical and Codman surgical instruments business, related primarily to employee compensation in our Symmetry Surgical segment.

General and Administrative Expenses. For the three month period ended September 29, 2012, general and administrative expenses increased $1,997 or 22.9%, to $10,730 from $8,733 in the comparable period in 2011. Significant items which impacted general and administrative expenses included:

	Three Months Ended
	September 29, 2012
				As a %
	Dollars			of Revenue
	(unaudited)

2011 period reported General &Administrative expenses	$	8,733			10.4	%
Impact due to acquired businesses		926
Change in amortization of intangible assets		1,295
Management transition expenses		(419	)
Change in stock compensation		819
Foreign currency impact		-
Other		(624	)
2012 period reported General & Administrative expenses	$	10,730			10.6	%

The impact due to acquired businesses reflects higher costs from the acquisitions of Olsen Medical and Codman surgical instruments business, related primarily to employee compensation in our Symmetry Surgical segment. Additionally, intangible assets were acquired with both Olsen Medical and Codman which resulted in an increase of amortization expense. Management transition expenses of $477, which primarily consist of stock and incentive compensation, were incurred in the 2011 period related to the appointment of our new CEO with minimal comparable expenses incurred in 2012. Other expenses were reduced primarily as a result of $356 of SEC-related legal costs incurred in 2011.

Facility Closure and Severance. Results of Operations include pre-tax charges of ($76) and $253 for the three months ended September 29, 2012 and October 1, 2011, respectively, associated with employee cost efficiency actions and employee severance costs. As of September 29, 2012, severance accruals related to these cost reduction and efficiency actions totaled $208 and were included in other accrued liabilities in the condensed consolidated balance sheets.

Operating Income (loss). For the three month period ended September 29, 2012, operating income (loss) was as follows:

	OEM Solutions					Symmetry Surgical					Unallocated						Consolidated Total
			As a %					As a %						As a %					As a %
	Dollars		of Revenue			Dollars		of Revenue			Dollars			of Revenue			Dollars		of Revenue
	(unaudited)

2011 period reported operating income (loss)	$	3,957		5.3	%	$	384		3.6	%	$	(2,679	)		-3.1	%		1,662		2.0	%
Impact of gross profit and SG&A		5,113		6.2	%		3,914		13.7	%		(846	)		-0.3	%		8,181		7.8	%
Facility closure and severance		324		0.4	%		-		0.0	%		5			0.0	%		329		-1.3	%
2012 period reported operating income (loss)	$	9,394		11.9	%	$	4,298		17.3	%	$	(3,520	)		-3.4	%	$	10,172		10.1	%

On a consolidated basis, operating income (loss) increased $8,510, or 512.0% for the three month period ended September 29, 2012 as compared to the 2011 period due to an increase in Symmetry Surgical operating income of $3,914 in addition to an increase in OEM Solutions operating income of $5,437 partially offset by an increase in unallocated costs of $841. Symmetry Surgical operating income increased by $3,914 and was 17.3% of segment revenue in the 2012 period as compared to operating income of $384 in 2011 primarily due to the acquisitions of Olsen Medical and Codman surgical instruments discussed previously. OEM Solutions operating income improved by $5,437 and was 11.9% of segment revenue in the 2012 period as compared to 5.3% in the prior year period due to increases in revenue and gross profit in addition to lower impact of facility closure and severance costs discussed previously. Unallocated costs increased by $841 in the 2012 period as compared to operating expense of ($2,679) in 2011 primarily due to increased stock compensation expense of $819 and a $160 increase in acquisition related costs, partially offset by the reduction of $419 in management transition expenses and $356 in SEC-related legal costs

Other (Income) Expense. Interest expense for the three month period ended September 29, 2012 increased $3,773, or 391.4%, to $4,737 from $964 for the comparable period in 2011. This increase is attributable to the increase in debt of $121,052 as compared to third quarter 2011, of which the Bank Term Loan bears interest at 14%. In addition, there was an increase in our applicable margin applied to variable rate debt by 150 basis points due to our increased leverage ratio associated with our 2011 acquisitions of Olsen Medical and the surgical instrumentation business of Codman.

The derivatives valuation gain consists of foreign currency forward contracts which are used to mitigate the effect of changes in the foreign exchange rates on net income. We recorded a gain of $116 for the three months ended September 29, 2012, which is a result of fluctuation in the Euro versus the US Dollar.

Other income for the three month period ended September 29, 2012 and October 1, 2011 represents foreign currency exchange rate fluctuations on transactions denominated in foreign currencies.

Provision for Income Taxes. Our effective tax rate was 33.9% for the three month period ended September 29, 2012 as compared to 38.6% for the three month period ended October 1, 2011. Provision for income taxes increased by $1,590, or 480.4%, to $1,921 for the three month period ended September 29, 2012 from $331 for the comparable 2011 period primarily due to a $4,801 increase in pre-tax income. Our effective tax rate in 2012 differed from the U.S. Federal statutory rate of 35% due primarily to the favorable impact of foreign taxes.

Nine Months Results of Operations

Revenue. Revenue for the nine month period ended September 29, 2012 increased $29,411, or 10.7%, to $303,949 from $274,538 for the comparable 2011 period. Revenue for each of our segments and principal product categories in these periods was as follows:

	Nine Months Ended
	September 29,		October 1,		Dollar			Percent
Sales by product	2012		2011		Change			Change
	(unaudited)
OEM Solution Revenue
Instrument	$	85,197	$	87,933	$	(2,736	)		-3.1	%
Implant		75,499		80,436		(4,937	)		-6.1	%
Cases		44,569		59,952		(15,383	)		-25.7	%
Other		19,913		17,944		1,969			11.0	%
Total OEM Solution Revenue		225,178		246,265		(21,087	)		-8.6	%

Total Symmetry Surgical Revenue	$	78,771		28,273		50,498			178.6	%

Total Revenue	$	303,949	$	274,538	$	29,411			10.7	%

The $21,087 decrease in our OEM Solutions revenue resulted from decreased customer demand within our instruments, implants and cases product lines, in addition to unfavorable foreign currency exchange rate fluctuations of $3,649. These reductions were partially offset by increased demand in our other product line. Overall, we experienced reduced revenues of 8.5% from our five largest OEM customers which drove the primary decrease in revenue. OEM Solutions Instrument revenue decreased $2,736. This decrease was driven by lower revenue from our top five largest OEM customers of $2,998 related primarily to fewer and smaller customer launches, as well as unfavorable foreign currency fluctuation of $346, offset by increased demand from other customers. OEM Solutions Implant revenue decreased $4,937, driven by decreased revenue from our top five largest OEM customers of $4,703 as well as unfavorable foreign currency exchange rate fluctuations of $1,574, offset by increased demand from other customers. Cases revenue decreased $15,383 due primarily to lower revenue from our top five largest OEM customers of $7,920 associated with fewer and smaller customer launches. In addition, the decrease relates to soft customer demand in other medical industries as well as unfavorable foreign currency exchange rate fluctuations of $1,363. Increase in our OEM Solution Other product revenue was driven by increased demand and favorable pricing, offset by unfavorable foreign currency exchange rate fluctuations of $366.

The $50,498 increase in Symmetry Surgical revenue for the nine month period ended September 29, 2012 as compared to 2011 was primarily the result of the acquisition of the Codman surgical instruments business in December 2011 and Olsen Medical in August 2011 which added $46,612 of revenue in 2012 compared to the same period 2011. Excluding the contributions of the acquired businesses, revenue increased $3,886 due to broader product offerings and additional direct sales representation as compared to the prior year period.

Gross Profit. Gross profit for the nine month period ended September 29, 2012 increased $22,836, or 39.8%, to $80,141 from $57,305 for the comparable 2011 period. Gross margin as a percentage of revenue increased 5.5%, to 26.4% for the nine month period ended September 29, 2012 from 20.9% for the comparable 2011 period.

	Nine Months Ended
	September 29, 2012
				As a %
	Dollars			of Revenue
	(unaudited)

2011 period reported gross profit	$	57,305			20.9	%
Change in organic sales		(2,829	)		0.0	%
Impact of acquisitions		29,129			6.4	%
Foreign currency impact		(719	)		0.0	%
Manufacturing costs and other		(2,745	)		-0.9	%
2012 period reported gross profit	$	80,141			26.4	%

Gross profit was favorably impacted by $29,129 due to the acquisitions of Olsen Medical and Codman surgical instruments within our Symmetry Surgical segment. Olsen Medical was acquired during third quarter 2011 and therefore contributed slightly to gross profit in the prior year period. The Codman surgical instruments business was acquired subsequent to October 1, 2011, therefore did not contribute to gross profit in the prior year period. Excluding the impact of newly acquired businesses and the change in foreign exchange rates, organic revenue declined by $13,552 which adversely impacted gross profit by approximately $2,829. Further, the adverse impacts to gross profit from manufacturing costs relate primarily to our decreased leveraging of overhead costs resulting from lower OEM Solution sales volume, partially offset by improvements in scrap and consumables, and efficiencies resulting from our lean initiatives.

Research and Development Expenses. For the nine month period ended September 29, 2012, research and development expenses remained relatively flat to the comparable period in 2011.

Sales and Marketing Expenses. For the nine month period ended September 29, 2012, sales and marketing expenses increased $6,514 or 48.8%, to $19,868 from $13,354 in the comparable period in 2011. Significant items which impacted sales and marketing expenses included:

	Nine Months Ended
	September 29, 2012
				As a %
	Dollars			of Revenue
	(unaudited)

2011 period reported Sales and Marketing expenses	$	13,354			4.9	%
Impact of acquisitions		8,091
Foreign currency impact		(104	)
Other		(1,473	)
2012 period reported Sales and Marketing expenses	$	19,868			6.5	%

The impact of acquisitions reflects higher costs from the acquisitions of Olsen Medical and Codman surgical instruments business, related primarily related to employee compensation in our Symmetry Surgical segment.

General and Administrative Expenses. For the nine month period ended September 29, 2012, general and administrative expenses (“SG&A”) increased $6,247 or 23.9%, to $32,331 from $26,084 in the comparable period in 2011. Significant items which impacted general and administrative expenses included:

	Nine Months Ended
	September 29, 2012
				As a %
	Dollars			of Revenue
	(unaudited)

2011 period reported General &Administrative expenses	$	26,084			9.5	%
Impact due to acquired businesses		2,274
Change in amortization of intangible assets		3,899
Management transition expenses		(2,989	)
Change in stock compensation		2,538
Foreign currency impact		(166	)
Other		691
2012 period reported General & Administrative expenses	$	32,331			10.6	%

The impact due to acquired businesses reflects higher costs from the acquisitions of Olsen Medical and Codman primarily related to higher employee sales and marketing compensation in our Symmetry Surgical segment. Additionally, intangible assets were acquired with both Olsen Medical and Codman which resulted in an increase of amortization expense. Stock compensation increased during 2012 due to performance based restricted stock awarded in 2012. Additionally, other expense increased as a result of professional service fees that have been incurred during the nine month period ended September 29, 2012 related to legal entity restructuring expenses and other tax planning initiatives that did not occur during 2011. Management transition expenses, which primarily consist of stock and incentive compensation, of $3,163 were incurred in the 2011 period related to the appointment of our new CEO with $174 incurred in 2012.

Facility Closure and Severance. Results of Operations include pre-tax charges of $596 and $2,526 for the nine months ended September 29, 2012 and October 1, 2011, respectively, associated with employee cost efficiency actions and employee severance costs. As of September 29, 2012, severance accruals related to these cost reduction and efficiency actions totaled $208 and were included in other accrued liabilities in the consolidated balance sheets.

Operating Income (loss).

	OEM Solutions						Symmetry Surgical						Unallocated						Consolidated Total
				As a %						As a %						As a %					As a %
	Dollars			of Revenue			Dollars			of Revenue			Dollars			of Revenue			Dollars		of Revenue
	(unaudited)

2011 period reported operating income (loss)	$	21,311			8.5	%	$	330			1.2	%	$	(9,331	)		-3.3	%		12,310		4.5	%
Impact of gross profit and SG&A		(4,272	)		-1.1	%		14,941			18.1	%		(561	)		0.2	%		10,108		2.9	%
Facility closure and severance		1,008			0.4	%		(186	)		-0.2	%		1,108			0.3	%		1,930		0.6	%
2012 period reported operating income (loss)	$	18,047			7.8	%	$	15,085			19.1	%	$	(8,784	)		-2.8	%	$	24,348		8.0	%

On a consolidated basis, operating income (loss) increased $12,038, or 97.8% for the nine month period ended September 29, 2012 as compared to the 2011 period due to an increase in Symmetry Surgical operating income of $14,755, as well as a decline in Unallocated costs of $547 partially offset by a decline in OEM Solutions operating income of $3,264. Symmetry Surgical operating income increased by $14,755 and was 19.1% of segment revenue in the 2012 period as compared to 1.2% in the prior year. The year over year increase was primarily due to the acquisitions of Olsen Medical and Codman as discussed previously. The decline in the Unallocated operating loss is related primarily to the reduction in management transition expenses of $2,989 associated with the appointment of our new CEO in 2011. OEM Solutions operating income declined by $3,264 and was 7.8% of segment revenue in the 2012 period as compared to 8.5% in the prior year period due to declines in revenue and gross profit partially offset by the lower impact of facility closure and severance costs.

Other (Income) Expense. Interest expense for the nine month period ended September 29, 2012 increased $12,151, or 441.2%, to $14,905 from $2,754 for the comparable period in 2011. This increase is attributable to the increase in debt of $121,052 as compared to third quarter 2011, of which the Bank Term Loan bears interest at 14%. Additionally, our applicable margin applied to variable rate debt increased by 150 basis points due to our increased leverage ratio associated with our 2011 acquisitions of Olsen Medical and Codman surgical instruments.

The derivatives valuation gain consists of foreign currency forward contracts entered into which are used to mitigate the effect of changes in the foreign exchange rates on net income. We recorded a gain of $179 for the nine months ended September 29, 2012, which is a result of fluctuation in the Euro versus the US Dollar.

Other income for the nine month period ended September 29, 2012 and October 1, 2011 represents foreign currency exchange rate fluctuations on transactions denominated in foreign currencies.

Provision for Income Taxes. Our effective tax rate was 39.1% for the nine month period ended September 29, 2012 as compared to 32.4% for the nine month period ended October 1, 2011. Provision for income taxes increased by $1,079, or 37.2%, to $3,980 for the nine month period ended September 29, 2012 from $2,901 for the comparable 2011 period due to a $1,219 increase in pre-tax income. Our effective tax rate in 2012 differed from the U.S. Federal statutory rate of 35% primarily due to the unfavorable impact of state taxes. Our effective tax rate increased from 32.4% in the 2011 period as compared to 39.1% in 2012 due primarily to increased pre-tax income in the United States principally related to the acquisitions of Olsen Medical and the surgical instruments business of Codman.

Liquidity and Capital Resources

Liquidity

Our principal source of liquidity in the nine month period ended September 29, 2012 was cash generated from operations. Principal uses of cash in the nine month period ended September 29, 2012 included capital expenditures and debt service. We expect that our principal uses of cash in the future will be to finance working capital, pay for capital expenditures, service debt and fund possible future acquisitions.

We believe our cash resources will permit us to stay committed to our strategic plan of increasing our share in the orthopedic market and expanding into other medical device segments and growing the business.

Operating Activities. Operating activities generated cash of $51,960 in the nine month period ended September 29, 2012 compared to $18,198 for the nine month period ended October 1, 2011, an increase of $33,762. The increase in cash from operations is primarily a result of the reduction in working capital. Net cash provided by working capital for the nine month period ended September 29, 2012 was $26,280 higher than the comparable 2011 period. Aggregate adjustments for non-cash items positively impacted operating cash flows by $7,342 primarily due to an increase in the amortization of intangible assets, debt issuance costs and interest paid-in-kind of $3,899, $1,036 and $1,002, respectively.

Investing Activities. Investing activities used $8,809 of cash in the nine month period ended September 29, 2012 compared to $21,313 in the nine month period ended October 1, 2011. Investing activities for the nine month period ending September 29, 2012 consisted of $9,128 for capital expenditures. The nine month period ended October 1, 2011, consisted of $10,426 for capital expenditures, as well as $11,000 related to the acquisition of Olsen Medical.

Financing Activities. Financing activities used $49,735 of cash in the nine month period ended September 29, 2012 compared to cash generated of $8,588 in the nine month period ended October 1, 2011, due primarily to payments on our Bank Revolver, short term borrowings and bank term loans and capital lease obligations. The nine month period ended October 1, 2011, included $7,500 of net proceeds from our Bank Revolver that reflects the incremental $11,000 of borrowings to fund the Olsen Medical acquisition.

Capital Expenditures

Capital expenditures totaled $9,128 for the nine months ended September 29, 2012, compared to $10,426 for the nine month period ended October 1, 2011. Expenditures were primarily for increased automation and replacement of existing equipment, as well as continued expansion and capability enhancement efforts in our Malaysia and Ireland facilities. We have also continued to enhance our automation as well as software costs associated with our Symmetry Surgical Epicor system implementation during 2012.

Debt and Credit Facilities

As of September 29, 2012, we had an aggregate of $224,642 of outstanding indebtedness, which consisted of $109,000 of borrowings on our Bank Revolver; $47,222 of a Bank Term Loan; $65,666 of Term Notes; $718 of borrowings under our Malaysia short-term credit facility; and $2,036 of capital lease obligations. We had two outstanding letters of credit as of September 29, 2012 in the amounts of $2,000 and $100.

Our Amended Credit Agreement and Term Notes contain various financial covenants, including covenants requiring a maximum ratio of total debt to EBITDA and minimum fixed charges ratio of EBITDA and a $30,000 letter of credit sublimit. As of September 29, 2012, the most restrictive covenants per the Corporation’s lending arrangements included the debt to EBITDA covenant ratio to be less than 4.50:1, and our ratio was approximately 3.7:1. The minimum interest coverage ratio requires us to be greater than 1.15:1, and our ratio at September 29, 2012 was approximately 1.7:1.

We intend to closely monitor our compliance with all of our debt covenants. We intend to closely monitor our revenues, cost of revenues and selling, general and administrative expenses to manage our ability to meet our debt covenant requirements. If we are unable to maintain compliance under our debt covenants, we could ultimately go into default under the terms of our various debt agreements.

We believe that cash flow from operating activities and borrowings on our Bank Revolver will be sufficient to fund currently anticipated working capital, planned capital spending and debt service requirements for the foreseeable future, including at least the next twelve months.

Off-Balance Sheet Arrangements

Our off-balance sheet arrangements include our operating leases and letters of credit, which are available under the Amended Credit Agreement. We had two letters of credit outstanding as of September 29, 2012 in the amounts of $2,000 and $100.

Environmental

Our facilities and operations are subject to extensive federal, state, local and foreign environmental and occupational health and safety laws and regulations. These laws and regulations govern, among other things, air emissions; wastewater discharges; the generation, storage, handling, use and transportation of hazardous materials; the handling and disposal of hazardous wastes; the cleanup of contamination; and the health and safety of our employees. Under such laws and regulations, we are required to obtain permits from governmental authorities for some of our operations. If we violate or fail to comply with these laws, regulations or permits, we could be fined or otherwise sanctioned by regulators. We could also be held responsible for costs and damages arising from any contamination at our past or present facilities or at third-party waste disposal sites. We cannot completely eliminate the risk of contamination or injury resulting from hazardous materials, and we may incur material liability as a result of any contamination or injury.

We incurred minimal capital expenditures for environmental, health and safety in the nine month periods ended September 29, 2012 and October 1, 2011

In connection with past acquisitions, we completed Phase I environmental assessments and did not find any significant issues that we believe needed to be remediated. We updated those Phase I assessments in conjunction with providing security for financing for the Codman acquisition and found no issues at that time either. Based on information currently available, we do not believe that we have any material environmental liabilities. We cannot be certain, however, that environmental issues will not be discovered or arise in the future related to these acquisitions.

Critical Accounting Policies and Estimates

The preparation of our consolidated financial statements in accordance with accounting principles generally accepted in the United States requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the periods presented. Our Annual Report on Form 10-K for fiscal year ended December 31, 2011, includes a summary of the critical accounting policies we believe are the most important to aid in understanding our financial results. There have been no material changes to these critical accounting policies that impacted our reported amounts of assets, liabilities, revenues or expenses during the nine months ended September 29, 2012.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

For financial market risks related to changes in interest rates, foreign currency exchange rates, commodity prices and the effects of inflation, reference is made to Item 7a “Quantitative and Qualitative Disclosures About Market Risk” contained in Part II of our Annual Report on Form 10-K for the fiscal year ended December 31, 2011. Our exposure to these risks, at the end of the third quarter covered by this report, has not changed materially since December 31, 2011.

ITEM 4. CONTROLS AND PROCEDURES

This Report includes the certifications of our Chief Executive Officer and Chief Financial Officer required by Rule 13a-14 of the Securities Exchange Act of 1934 (the “Exchange Act”). See Exhibits 31.1 and 31.2. This Item 4 includes information concerning the controls and control evaluations referred to in those certifications.

(a) Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures.

In connection with the preparation of this Report, our management, under the supervision and with the participation of the Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the fiscal quarter covered by this report on Form 10-Q. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of September 29, 2012.

(b) Changes in Internal Control over Financial Reporting

There have been no changes in our “internal control over financial reporting” (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during the fiscal quarter covered by this report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting, except that, during the fiscal quarter of this report, we were still in the process of integrating the Codman surgical instruments operations. See Note 2 to the condensed consolidated financial statements included in Item 1 for a discussion of the Codman surgical instruments acquisition.

(c) Other Matters

The Corporation is in the process of integrating its multiple Symmetry Surgical operations into its existing Enterprise Resource Planning (ERP) platform. An ERP system is a fully-integrated set of programs and databases that incorporate order processing, planning and scheduling, purchasing, accounts receivable and inventory management and accounting. In connection with this ERP consolidation, the Corporation will update its internal controls over financial reporting, as necessary, to accommodate modifications to its business processes and accounting procedures. The Corporation does not believe that this ERP system consolidation will have an adverse effect on the Corporation’s internal control over financial reporting.

PART II OTHER INFORMATION

ITEM 1A. RISK FACTORS

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A “Risk Factors” contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011, which could materially affect our business, financial condition or future results. There have been no material changes from the risk factors disclosed in our Annual Report on Form 10-K.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

The following information is provided pursuant to Item 703 of Regulation S-K:

Issuer Purchases of Equity Securities
Period	(a) Total Number of Shares (or Units) Purchased		(b) Average Price paid per Share (or Unit)		(c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs		(d) Maximum Number (0r Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs
July 2012		647	$	8.58		-		-

The shares repurchased represent shares of our common stock that employees elected to surrender to the Corporation to satisfy their tax withholding obligations upon the vesting of shares of restricted stock. We do not consider this a share buyback program.

ITEM 6. EXHIBITS

31.1		Certification of Chief Executive Officer required by Item 307 of Regulation S-K as promulgated by the Securities and Exchange Commission and pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
31.2		Certification of Chief Executive Officer required by Item 307 of Regulation S-K as promulgated by the Securities and Exchange Commission and pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
32.1		Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 furnished with this document.*
101.INS		XBRL Instance Document. ~
101.SCH		XBRL Taxonomy Extension Schema Document. ~
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document. ~
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document. ~
101.LAB		XBRL Taxonomy Extension Label Linkbase Document. ~
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document. ~

* Filed concurrently herewith.

~ In accordance with Rule 406T under Regulation S-T, the XBRL-related information in Exhibit 101 shall be deemed “furnished” and not “filed.”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	SYMMETRY MEDICAL INC.

	By	/s/ Thomas J. Sullivan
		Thomas J. Sullivan,
		President and Chief Executive Officer
		(Principal Executive Officer)

	By	/s/ Fred L. Hite
		Fred L. Hite,
		Senior Vice President and Chief Financial Officer
		(Principal Financial Officer)

November 8, 2012